Literature DB >> 4051860

Clearance of triamcinolone from vitreous.

G N Scholes, W J O'Brien, G W Abrams, M F Kubicek.   

Abstract

The clearance of intravitreally injected triamcinolone acetonide was monitored by both indirect ophthalmoscopy and high-performance liquid chromatography (HPLC) and found to be more rapid than previously reported by others. Twenty-four rabbits were intravitreally injected in each eye with 0.4 mg of triamcinolone acetonide. Three rabbits each were sacrificed at intervals ranging from one hour to 46 days. The vitreous was then harvested and processed for HPLC analysis. Triamcinolone and the internal standard prednisolone were identified and quantitated by the use of HPLC, which was found to be both sensitive and specific for the steroids. The half-life as determined by HPLC was 1.6 days, the level at 13 days postinjection was 66 +/- 19 micrograms, and no drug was detectable by HPLC analysis at 21 days in five of six eyes. The intravitreal masses thought to be triamcinolone were clinically observable to an average of 23.3 days. The chromatographically determined clearance rate did not correlate well with clinical impressions based on indirect ophthalmoscopy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4051860     DOI: 10.1001/archopht.1985.01050100143037

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  23 in total

1.  Pharmacokinetics and safety of intravitreally delivered etanercept.

Authors:  Sascha Fauser; Hubert Kalbacher; Nils Alteheld; Kan Koizumi; Tim U Krohne; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-17       Impact factor: 3.117

2.  Intraocular concentration of intravenous prednisolone in experimental autoimmune uveoretinitis mice.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Yukio Arakawa; Nobuo Kurokawa; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2006 Nov-Dec       Impact factor: 2.447

3.  Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep.

Authors:  Tugba Cakmak Argun; Ozlem Yalcin Tok; Levent Tok; Gulsen Yilmaz; Fatma Meric Yilmaz; Alime Gunes; Mehmet Argun; Osman Butuner
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

4.  Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis.

Authors:  Seung Youn Jea; Ik Soo Byon; Boo Sup Oum
Journal:  Korean J Ophthalmol       Date:  2006-06

5.  Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye.

Authors:  J J Chen; S E Ebmeier; W M Sutherland; N G Ghazi
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

6.  Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation.

Authors:  Kenan Sonmez; Faruk Ozturk
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

7.  Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study.

Authors:  K-H Sonoda; H Enaida; A Ueno; T Nakamura; Y-I Kawano; T Kubota; T Sakamoto; T Ishibashi
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

8.  Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy.

Authors:  Masako Oishi; Shinichiro Maeda; Noriyasu Hashida; Nobuyuki Ohguro; Yasuo Tano; Nobuo Kurokawa
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

9.  Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.

Authors:  Seong Joon Ahn; Hye Kyoung Hong; Young Mi Na; Sang Jun Park; Jeeyun Ahn; Jaeseong Oh; Jae Yong Chung; Kyu Hyung Park; Se Joon Woo
Journal:  J Vis Exp       Date:  2016-07-23       Impact factor: 1.355

10.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.